Voyager Therapeutics (Nasdaq: VYGR) has entered a strategic collaboration and license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance…
January 03, 2024
CollPlant Biotechnologies Evaluates 3D-Bioprinted Regenerative Breast Implants in Preclinical Study
Regenerative and aesthetics medicine company, CollPlant Biotechnologies (Nasdaq: CLGN) has initiated a preclinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants. There is currently no…
January 02, 2024
Bright Minds Announces Positive Topline Data for Potential Psychosis and Addiction Treatment
Bright Minds Biosciences Inc. (Nasdaq: DRUG) has announced the successful completion of its three-part Phase 1 study of BMB-101. The study, conducted in Adelaide, Australia,…
December 29, 2023
Codexis Partners with Nestlé Health Science in Promising EPI Treatment Deal Worth Up to $45M
Codexis, Inc. (NASDAQ: CDXS) has signed a purchase agreement with Nestlé Health Science for CDX-7108, a therapy aimed at treating exocrine pancreatic insufficiency (EPI). The…
December 20, 2023
PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success
Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is celebrating a year of strategic accomplishments on its first anniversary as a public company. Lipella is advancing…
December 20, 2023
Structure Therapeutics Falls 41% on GLP-1 Drug Update
Structure Therapeutics Inc. (Nasdaq: GPCR) has provided a program update for its highly selective oral GLP-1 receptor agonist, GSBR-1290. The drug demonstrated clinically meaningful activity…
Panbela Therapeutics, Inc. (Nasdaq: PBLA) has announced that US WorldMeds®1 (USWM) has received FDA approval of its New Drug Application (NDA) for the use of…
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has been granted FDA clearance for its Investigational New Drug Application (IND) for NRX-101 for the treatment of complicated Urinary…
Global healthcare company, Organon (NYSE: OGN), has entered an agreement with Eli Lilly and Company (NYSE: LLY) to become the sole distributor and promoter for…
December 18, 2023
Biotech Breakfast – Verrica Pharmaceuticals Soars, Healthcare Equities Dip & Cancer Vaccine Advances
Healthcare equities finished mostly lower following an uneventful day on Friday. Healthcare fell by (0.85%) versus the S&P 500 which was down (0.01%). It was…
December 18, 2023
MindMed Advances Treatment for Generalized Anxiety Disorder
Biopharmaceutical company, Mind Medicine (Nasdaq: MNMD) has announced positive results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD)….
December 15, 2023
“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company’s lead drug candidate for amyotrophic…